BioPharma Resources

Investigational drug · Phase 3

NXT007

Also called: Zemocimig, RO7589655, RG6512

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hemophilia A.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

5

Any phase or sponsor naming "NXT007"

First trial start

2023

Sep 21, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "NXT007", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Hemophilia A

Approved drugs for the same conditions: Hemophilia · Hematology and blood cancers

Largest trials

Live from ClinicalTrials.gov: studies naming "NXT007" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 13 on PubMed

Also in development for Hemophilia A

  • SR604Phase 34 trials

    Shanghai RAAS Blood Products Co., Ltd. · Factor VII Deficiency, Hemophilia A, Hemophilia B

  • BIVV001efanesoctocog, AltuvoctPhase 33 trials

    Swedish Orphan Biovitrum · Haemophilia A (Moderate or Severe), Hemophilia A, Hemophilia A, Severe

  • GS1191-0445Phase 32 trials

    Gritgen Therapeutics Co., Ltd. · Severe Hemophilia A, Hemophilia A

  • Valoctocogene roxaparvovecBMN 270, GENEr8Phase 32 trials

    BioMarin · Hemophilia A, Hemophilia A With Inhibitor, Hemophilia A With Anti Factor VIII

  • ARD001Phase 21 trial

    Arditus Pte Ltd · Hemophilia A, Healthy Adult Participants

  • ASC618Phase 21 trial

    ASC Therapeutics · Hemophilia A

  • BAY2599023DTX201Phase 21 trial

    Bayer · Hemophilia A

  • SPK-8011QQRO7878488Phase 21 trial

    Roche (Genentech) · Hemophilia A

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.